01762oam 2200433 450 991070702150332120161017094820.0(CKB)5470000002461276(OCoLC)945734630(EXLCZ)99547000000246127620160331d2016 ua 0engurbn||||a||||txtrdacontentcrdamediacrrdacarrierExamining concerns regarding FDA's proposed changes to generic drug labeling hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, April 1, 2014Washington :U.S. Government Publishing Office,2016.1 online resource (v, 146 pages)Title from title screen (viewed on Mar. 31, 2016).Paper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office."Serial No. 113-132."Includes bibliographical references.Examining concerns regarding FDA's proposed changes to generic drug labeling Generic drugsLabelingUnited StatesDrugsSafety regulationsUnited StatesWarning labelsGovernment policyUnited StatesLegislative hearings.lcgftGeneric drugsLabelingDrugsSafety regulationsWarning labelsGovernment policyGPOGPOSTFGPOBOOK9910707021503321Examining concerns regarding FDA's proposed changes to generic drug labeling3504464UNINA